FOR AUTHORS
2025: XXXI Congresso Nazionale Intergruppo Melanoma Italiano (IMI)
Published:
11 December 2025
XXXI Congresso Nazionale Intergruppo Melanoma Italiano (IMI)
-
01 | End-of-life care in advanced melanoma and other skin cancers: a retrospective cohort from an Italian comprehensive cancer center Michela De Mattia1, Enrica Teresa Tanda3, Andrea Boutros2, Virginia Delucchi5, Eva Blondeaux5, Agostina Lagodin D’Amato1, Irene Giannubilo1, Lucia Del Mastro1|2, Paolo Pronzato3, Francesco Spagnolo3|4, Claudia Bighin3 | 1Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova; 2U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova; 3U.O. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova; 4Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate, Università di Genova, Genova; 5U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
466 -
02 | Melanoma training in primary care: comparing traditional teaching with telemedicine-enhanced education. A review Giorgia Ravaglia1, Edoardo Mora2, Debora Cantagalli3, Serena Magi4, Laura Mazzoni4, Matelda Medri4, Cesare Massone5, Davide Melandri6, Federica Zamagni7, Ines Zanna8, Gianluca Pistore9, Saverio Caini8, Salvatore Amato10, Vincenzo De Giorgi11, Pietro Quaglino12, Maria Antonietta Pizzichetta13|14, Giovanni Luigi Tripepi15, Sofia Spagnolini1, Ignazio Stanganelli1|4 | 1Dermatology Resident Training Program, Department of Medicine and Surgery, University of Parma, Parma; 2Dermatology Unit, Ospedale S. Anna, Como; 3Primary Care Resident Training program, Ausl Bologna, Bologna; 4Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST Meldola, Forlì-Cesena; 5Dermatology Unit, Ospedali Galliera, Genova; 6Dermatology Unit, AUSL Romagna and University of Bologna, Cesena. 7Registro Tumori della Regione Emilia Romagna, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Meldola, Forlì-Cesena; 8Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, Florence; 9Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata - IRCCS, Rome; 10Associazione Dermatologi Ospedalieri Italiani, ADOI, Sicilia and Teledermatology working group, Palermo; 11Dermatology, Department of Health Sciences, University of Florence, Florence; 12Dermatologic Clinic, Department of Medical Sciences, University of Turin, Torino; 13Department of Dermatology, University of Trieste, Trieste; 14Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, CRO, IRCCS, Aviano; 15CNR-IFC, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy.
376 -
03 | Pancreatic cancer burden in Italian CDKN2a-positive families followed for up to 25 years Eleonora Allavena1|2, Bruna Dalmasso2, Andrea Gambino2, Francesca Barbero2, Irene Vanni2, Cansu Gorgun1, Francesco Spagnolo2|4, Enrica Tanda3, Andrea Boutros3, William Bruno1|2, Lorenza Pastorino1|2, Paola Ghiorzo1|2 | 1Department of Internal Medicine and Medical Specialties - DiMI, University of Genoa; 2Cancer Genetics Unit, IRCCS Ospedale Policlinico San Martino, Genoa; 3Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genoa; 4Department of Surgical and Diagnostic Integrated Sciences, University of Genoa, Genoa, Italy.
348 -
04 | Association of a novel TERT polymorphism with poorer survival in male patients with melanoma Fortunato Cassalia1, Maria Santa Rocca2, Andrea Di Nisio3, Paolo del Fiore*4, Clara Benna5|7, Ilaria Cosci6, Simone Mocellin4|5, Alberto Ferlin*2|6 | 1Department of Dermatology, University of Padua, Padua; 2Unit of Andrology and Reproductive Medicine, University Hospital of Padua, Padua; 3Department of Wellbeing, Nutrition and Sport, Pegaso Telematic University, Naples; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 5Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 6Department of Medicine, University of Padua, Padua; 7Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
347 -
05 | Revisiting cancer risk associated with the MITF p.e318k variant beyond melanoma Debora Tonello1, Beatrice Zennaro1, Stefania Pellegrini1, Monica Quaggio2, Luisa Piccin3, Alessio Fabozzi4, Luigi Dall’Olmo2|5, Saveria Tropea5, Maria Chiara Scaini1, Chiara Menin1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova; 2Department of Surgery, Oncology and Gastroenterology, Section of Immunology and Oncology, AIDS Reference Center, University of Padova, Padova; 3Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova; 4Oncology Unit 3, Veneto Institute of Oncology - IOV-IRCCS, Padua; 5Soft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
342 -
06 | SUNTEL program: first experience of school integration of the ugly duckling sign with e-learning and peer education for melanoma awareness Giorgia Ravaglia1, Serena Magi2, Elisabetta Costa3, Matelda Medri2, Franca Gentilini4, Chiara Scutellà4, Daniela De Zerbi5, Silvia Gerosa1, Federica Zamagni6, Chiara Doccioli7, Sara Gandini8, Maria Costanza Cipullo9, Saverio Caini7, Ignazio Stanganelli1|2 | 1Dermatology Resident Training Program, Department of Medicine and Surgery, University of Parma, Parma; 2Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST Meldola, Forlì-Cesena; 3Graphic Design and Multimedia "Good Sun Good Skin" project, Istituto Oncologico Romagnolo, Forlì; 4IOR Scuola, Istituto Oncologico Romagnolo, Forlì; 5Scientific High School "Alfredo Oriani", Ravenna; 6Emilia-Romagna Cancer Registry, Romagna Unit, IRCCS IRST Romagnolo Institute for the Study of Tumors "Dino Amadori", Meldola, Forlì-Cesena; 7Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention, and Clinical Network, ISPRO, Florence; 8Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan; 9Directorate General for Student Affairs, Inclusion, and Career Guidance, Prevention and Health Education Unit, Ministry of Education, Rome, Italy.
330 -
07 | Early diagnosis of melanoma in the era of non-invasive imaging: histopathological confirmation of malignancy vs. clinical suspicion. a retrospective study of 2240 patients Giovanni Cecchi1, Gabriella Perillo1, Federica Fazzari1, Virginia Marabini2, Biancamaria Zuccaro1, Vincenzo De Giorgi1 | 1Dipartimento di Scienze della Salute, Sezione di Dermatologia, Università di Firenze; 2Dipartimento di Scienze della Salute, Università di Firenze, Italy.
312 -
08 | Cutaneous melanoma and occupational UV exposure: associations with anatomical site, histological subtype, and Breslow thickness Federica Fazzari, Giovanni Cecchi, Gabriella Perill, Biancamaria Zuccaro, Vincenzo De Giorgi | Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
336 -
09 | Integration of hematoxylin and eosin and immunohistochemistry images to improve AI-based recurrence prediction in negative sentinel lymphnode melanoma patients Maria Colomba Comes1, Andrea Lupo1, Fabio Mele2, Concetta Saponaro2, Arianna Bozzi1, Ivana De Risi3, Samantha Bove1, Annarita Fanizzi1, Benedetta Apollonio3, Margherita Sonnessa2, Sabino Strippoli3, Francesco Alfredo Zito2, Michele Guida3, Raffaella Massafra1 | 1Biostatistics and Bioinformatics Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 2Pathology Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 3Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
316 -
10 | Prognostic value of trans epidermal water loss in the treatment of actinic keratoses. A comparison amongst topical therapies for field cancerization Matteo Bevilacqua, Filippo Fanetti, Nicolò Mori, Agata Janowska, Valentina Dini, Marco Romanelli | Department of Dermatology, University of Pisa, Pisa, Italy.
369 -
11 | Challenges in developing a digital pathology consultation network: insights from the MELCAYA experience Filippo Ugolini1, Dario Di Gangi2, Roberta Gugliotta3, Anna Szumera-Ciećkiewicz4|5, Llucia Alos6, Natalia Castrejón6, Stephan Forchhammer7, Barbara Valeri8, Nicolas Macagno9, Sule Ozturk Sari10, Ozge Hurdogan10, Sokol Sina11, Sylvie Fraitag12, Valerio Gaetano Vellone13, Chiara Trambaiolo13, Rita Alaggio14, Sabrina Rossi14, Giovanni Arcuri3, Daniela Massi2, Claudio Conti3 | 1Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy. 2Section of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy. 3UOC Direzione Tecnica, ICT ed Innovazione Tecnologie Sanitarie, Fondazione Policlinico Agostino Gemelli IRCCS, Roma, Italy. 4Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 5Department of Pathology , Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 6Department of Pathology, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.7Department of Dermatology, University Medical Center, Eberhard Karls University Tübingen, Tübingen, Germany. 8Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 9Aix-Marseille University, Marmara Institute, INSERM, U1251, MMG, DOD-CET, Marseille, France. 10Department of Pathology, Istanbul University Istanbul Medical Faculty, Istanbul, Türkiye; 11Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 12Pathology Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; 13Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa; 14Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
373 -
12 | Integrated molecular and immunophenotypic profiling of uveal melanoma: prognostic insights and biological perspectives Francesco Fortarezza1, Giovanni Zarrilli2, Giada Munari1, Valentina Angerilli3, Mariangela Balistreri1, Luisa Piccin4, Valentina Salizzato4, Jacopo Pigozzo4, Giulia Midena5, Raffaele Parrozzani6, Valentina Guarneri4|7, Edoardo Midena5|6, Marta Sbaraglia1|8, Matteo Fassan8|9, Angelo Paolo Dei Tos1|8 | 1Surgical Pathology and Cytopathology Unit, Department of Integrated Diagnostics. Azienda Ospedale-Università Padova, Padua; 2Surgical Pathology Unit, Azienda Ulss 3 Serenissima, Ospedale dell'Angelo, Venezia; 3Department of Surgical Pathology, Azienda ULSS2 Marca Trevigiana, Treviso; 4Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 5IRCCS-Fondazione Bietti, Rome; 6Department of Ophthalmology, University of Padova, Padova; 7Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 8Department of Medicine, University of Padua School of Medicine, Padua; 9Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
309 -
13 | Spatial contexture of tertiary lymphoid structures as a predictor of recurrence in early-stage melanoma Chiara Bungaro1, Sabino Strippoli1, Daniele Carenza1, Ivana De Risi1, Rossella Villani1, Teresa Squicciarini1, Anna Albano1, Ileana De Roma1, Fabio Mele 2, Margherita Sonnessa2, Concetta Saponaro2, Francesco Alfredo Zito2, Arianna Bozzi3, Benedetta Apollonio1, Raffaella Massafra3, Michele Guida1 | 1Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 2Pathology Unit, IRCCS Istituto Tumori "Giovanni Paolo II"; 3Biostatistics and Bioinformatics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
337 -
14 | Unraveling the transcriptomic landscape of poorly differentiated cutaneous squamous cell carcinoma: toward prognostic biomarkers Lorenzo Bellando1, Chiara Anselmo2, Giulia Orlando3, Leonardo Panarelli2, Ilaria Palma2, Virginia Caliendo3, Franco Picciotto4, Gabriele Roccuzzo5, Pietro Quaglino5, Simone Ribero5, Rebecca Senetta3 | 1Pathology Unit, Città Della Salute e Della Scienza University of Turin; 2Department of Medical Sciences, Pathology Unit, University of Turin; 3Department of Oncology, Pathology Unit, University of Turin; 4Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza of Turin; 5Department of Medical Sciences, Section of Dermatology, University of Turin, Italy.
328 -
15 | Clinico-pathological features of superficial angiosarcomas: a retrospective study Lorenzo Bellando1, Chiara Anselmo2, Giulia Orlando3, Leonardo Panarelli2, Pietro Cosentino2, Pietro Quaglino4, Franco Picciotto5, Simone Ribero4, Rebecca Senetta3 | 1Pathology Unit, Città Della Salute e Della Scienza of Turin, University of Turin; 2Department of Medical Sciences, Pathology Unit, University of Turin; 3Department of Oncology, Pathology Unit, University of Turin; 4Department of Medical Sciences, Section of Dermatology, University of Turin; 5Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy.
332 -
16 | Sentinel lymph node biopsy in elderly patients with melanoma: prognostic value and impact on recurrence B. Taglione1, I. Mattavelli1, A. Maurichi1, G. Gallino1, D. Cortese1, A. Manfredi1, S. Mercurio1, G. Spadola1, E. Tolomio1, C. Barbieri1, B. Scoppio1, M. Cossa2, B. Valeri2, M. Santinami1, R. Patuzzo1 | 1IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Melanoma Surgical Unit, Milano; 2IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Pathology, Milano, Italy.
313 -
17 | The role of sentinel lymph node biopsy in pt1a, pt1b and pt2a melanomas: a 10-year experience through 2025 Gabriele Roccuzzo1, Nicolas Destefanis2, Giulia Orlando3, Eleonora Bergamo1, Virginia Caliendo4, Adriana Lesca5, Daniela Zugna2, Franco Picciotto4, Rebecca Senetta3, Simone Ribero1, Pietro Quaglino1 | 1Department of Medical Sciences, Section of Dermatology, University of Turin; 2Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin; 3Department of Oncology, Section of Surgical Pathology, University of Turin; 4Dermatologic Surgery Section, Department of Surgery, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin; 5Division of Nuclear Medicine, Department of Medical Science, University of Turin, Italy.
304 -
18 | Surgical management of pregnancy-associated melanoma: a single institution experience with thirty-three pregnant patients B. Taglione1, I. Mattavelli1, A. Maurichi1, G. Gallino1, D. Cortese1, E. Tolomio1, G. Spadola1, C. Barbieri1, S. Mercurio1, B. Scoppio1, B. Valeri2, M. Cossa2, M. Maccauro3, L. Di Guardo4, M. Del Vecchio4, M. Santinami1, R. Patuzzo1 | 1IRCCS Istituto Nazionale Tumori Milano, Surgery, Milano; 2IRCCS Istituto Nazionale Tumori Milano, Pathology, Milano; 3IRCCS Istituto Nazionale Tumori Milano, Nuclear Medicine, Milano; 4IRCCS Istituto Nazionale Tumori Milano, Medical Oncology, Milano, Italy.
338 -
19 | Late draining lymph nodes on preoperative lymphoscintigraphy in melanoma patients: preliminary data from a retrospective study of over 400 cases Tiziano Pallara, Giovanni Marruzzo, Emilia Migliano | UOSD Chirugia Plastica ad Indirizzo Dermatologico e Rigenerativo, IRCCS IFO Istituto San Gallicano, Roma, Italy.
283 -
20 | How Covid-19 pandemic influenced the diagnosis of new primary melanoma: a retrospective, multicenter study by the Italian Society of Oncological Surgery Giuseppe Sciacca*1|2, Luca Nespoli1, Virginia Caliendo2, Dario Piazzalunga3, Piero Rossi4, Marco Clementi5, Corrado Caracò6, Salvatore Asero7, Matteo Mascherini8, Franco De Cian8, Francesco Russano9, Paolo Del Fiore9, Sara Coppola10, Elisabetta Pennacchioli10, Pietro Gallina11, Marzia Franzò12, Marco Rastrelli9|12 | 1General and Emergency Surgery, School of Medicine and Surgery, Milano-Bicocca University, Fondazione IRCCS San Gerardo dei Tintori, Monza; 2Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin; 3Unit of Surgery, Papa Giovanni XXIII Hospital, Bergamo; 4Dipartimento Di Scienze Chirurgiche, Università di Roma Tor Vergata, Policlinico Tor Vergata, Rome; 5General Surgical Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 6Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori "Fondazione Pascale" IRCCS, Napoli; 7Soft Tissue U.O. Surgical Oncology-Soft Tissue Tumors, Dipartimento di Oncologia, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania; 8Department of Surgical Sciences and Integrated Diagnostic DISC, University of Genoa; 9Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova; 10Division of Melanoma, Soft Tissue Sarcomas and Rare Tumors, European Institute of Oncology, IRCCS, Milano; 11Directorate General, Veneto Institute of Oncology IOV-IRCCS, Padua; 12Department of Surgery, Oncology and Gastroenterology, DISCOG, University of Padua, AOPD Azienda Ospedale Università Padova, Padova, Italy.
346 -
21 | Melanoma in situ: long-term outcomes and follow-up strategies based on risk stratification Beatrice De Checchi1, Paolo del Fiore2, Irene Russo2, Chiara Trevisiol2, Marco Domenico Mazza2, Saveria Tropea2, Francesco Russano2, Mauro Alaibac3, Carlomaria Gianesini4, Giovanni Madeo4, Simone Mocellin2|4 | 1Department of Medicine, University of Padua, Padua; 2Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 3Department of Dermatology, University of Padua; 4Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
309 -
22 | Surgical radicality and reconstructive techniques in melanoma and non-melanoma skin cancer A. Lenta, A. Amore, L. Benedetto, C. Caracò | Chirurgia del Melanoma e dei tumori cutanei, Istituto Nazionale Tumori "Fondazione Pascale", Napoli, Italy.
312 -
23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*1, Teresa Amaral*2, Piotr Rutkowski*3, Marie-Lena Rasch2, Naima Benannoune4, Patricio Serra5, Maria Grazia Vitale6, Diana Giannarelli7, Ana Maria Arance8, Eva Munoz Couselo9, Bart Neyns10, Iris Dirven11, Marco Tucci12, Michele Guida13, Francesco Spagnolo14, Ernesto Rossi15, Paola Queirolo16, Pietro Quaglino17, Roberta Depenni18, Joanna Placzke3, Anna Maria Di Giacomo19, Michele Del Vecchio20, Alice Indini20, Ines Pires da Silva21, Alexander M. Menzies22, Angela Hong23, Paul Lorigan5, Caroline Robert24, Georgina V. Long22, Paolo A. Ascierto6, Mario Mandalà25 | 1Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; 2Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. 3Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4Gustave Roussy Cancer Campus, Villejuif, France. 5The University of Manchester, Manchester, UK. 6Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; 7Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 8Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; 9Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; 10Department of Medical Oncology, UZ Brussel, Brussels, Belgium. 11Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; 12Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. 13Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. 14IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; 15Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 16IEO European Institute of Oncology, IRCCS, Milan, Italy. 17Department of Dermatology, University of Turin, Turin, Italy. 18University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; 19Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. 20Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 21Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; 22Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; 23Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 24Gustave Roussy and Paris-Saclay University, Villejuif, France; 25Unit of Medical Oncology, University of Perugia, Perugia, Italy. § on behalf of the Italian Melanoma Intergroup - IMI.
292 -
24 | Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study Federico Venturi1|2|3, Biancamaria Zuccaro1, Gabriella Perillo1, Giovanni Cecchi1, Aurora Gaeta4|5, Sara Gandini4, Vincenzo De Giorgi1|6 | 1Section of Dermatology, Department of Health Sciences, University of Florence; 2Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna; 3Department of Medical and Surgical Sciences, DIMEC, Alma Mater Studiorum University of Bologna; 4Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan; 5Department of Statistics and Quantitative Methods, University of Milano-Bicocca; 6Cancer Research "Attilia Pofferi" Foundation, Pistoia, Italy.
300 -
25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo1|2, Carlo Resteghini1|2, Sara Farinatti1|2, Andrea Alberti3, Valeria Tovazzi3, Paola Queirolo4, Maristella Saponara4, Giuseppe Argenziano5, Riccardo Marconcini6, Ketty Peris7, Paola Savoia8, Maria Chiara Tronconi1, Iris Zalaudek9, Paolo Ascierto10, Francesco Spagnolo11, Luigi Lorini1, Cristina Gurizzan1, Paolo Bossi1|2 | 1Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano MI; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; 3Medical Oncology Unit, ASST Spedali Civili, Brescia; 4Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; 5Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 6Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Department of Health Sciences, University of Eastern Piedmont, Novara; 9Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; 10Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; 11Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
320 -
26 | Tumor size may predict early response to sonidegib in locally-advanced basal cell carcinoma: clinical and histopathological correlates from a monocentric case series Gabriella Perillo1, Giovanni Cecchi1, Biancamaria Zuccaro1, Federica Fazzari1, Vincenzo De Giorgi1|2 | 1Section of Dermatology, Department of Health Sciences, University of Florence; 2Cancer Research "Attilia Pofferi" Foundation, Pistoia, Italy.
281 -
27 | Real-world data for malignant melanoma stage II adjuvant therapy Silvana Cozzolino1, Antonino Colloca1, Miriam Forte1, Francesco Caraglia1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Maria Chiara Sergi3, Teresa Del Giudice4, Francesca Sparano5, Immacolata Paciolla6, Mariangela Pasqualoni7, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi1, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples; 2Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy; 3Division of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples; 6Medical Oncology Unit, AORN "San Pio", Benevento, Italy; 7Medical Oncology Unit, ASL Taranto, Italy.
336 -
28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte1, Francesco Caraglia1, Silvana Cozzolino1, Antonino Colloca1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Francesca Sparano5, Maria Chiara Sergi3, Teresa Del Giudice4, Immacolata Paciolla6, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi6, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; 2Department of Clinical Medicine and Surgery, Federico Il University, Naples; 3Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; 6Medical Oncology Unit AORN "San Pio", Benevento, Italy.
335 -
29 | The extracellular vesicle potential for the early detection of resistance to immunotherapy in melanoma patients Cristina Catoni1, Cristina Poggiana1, Alessandro Francesco Piazza1, Jacopo Pigozzo2, Luisa Piccin2, Chiara Menin1, Stefania Pellegrini1, Valentina Salizzato2, Paolo Del Fiore4, Simone Mocellin3|4, Vanna Chiarion-Sileni2, Valentina Guarneri2|3, Antonio Rosato1|3, Maria Chiara Scaini1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 2Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 3Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
277 -
30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial) Sara Farinatti1|2, Giuseppe Agenziano3, Emi Dika4|5, Emanuela Passoni6, Ketty Peris7, Pietro Quaglino8, Paola Queirolo9, Massimiliano Scalvenzi10, Iris Zalaudek11, Luigi Lorini11, Cristina Gurizzan1, Monica Variolo1|2, Paolo Bossi*1|2, Carlo Resteghini*1|2 | 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; 2Department of Biomedical Sciences, Humanitas University, Rozzano MI; 3Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 4Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; 5Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; 6Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Dermatologic Clinic, University of Turin Medical School, Turin; 9Medical Oncology Unit; 10Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; 11Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed equally.
336 -
31 | Effectiveness and safety of adjuvant combo-targeted and immunotherapy in melanoma patients Valentina Salizzato1, Luisa Piccin1, Alessio Fabozzi2, Paolo Del Fiore3, Francesco Cavallin4, Chiara Cacco1|5, Simone Mocellin3|5, Marcodomenico Mazza3, Valentina Guarneri1|5, Jacopo Pigozzo1 | 1Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova; 2Medical Oncology 3, Veneto Institute of Oncology IOV-IRCCS, Padova; 3Soft-Tissue, Peritoneum and Melanoma Surgical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova; 4Independent Statistician, Solagna; 5Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy.
275 -
32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy Luisa Piccin1, Maria Chiara Scaini2, Valentina Salizzato1, Cristina Catoni2, Elisabetta Di Liso1, Alice Menichetti1, Chiara Cacco1|4, Chiara Gottardi1|4, Francesca Di Sarra3, Marina Coppola3, Valentina Guarneri1|4, Jacopo Pigozzo1 | 1Medical Oncology 2 - Veneto Institute of Oncology IOV-IRCCS; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS; 3Pharmacy Unit - Veneto Institute of Oncology IOV-IRCCS; 4Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
270 -
33 | A single center, real world experience with hedgehog pathway inhibitors in advanced basal cell carcinoma Giulia Gibilisco1, Ramiz Anwar Rana1, Vincenzo D’Alonzo1, Maura Colucci1|2, Monica Valente2, Elisa Cinotti3, Giovanni Rubino4, Valentina Croce1, Eleonora Carbonari1, Matteo Ravara1, Tommaso Sani1, Maria Lo Fiego1, Alessia Covre1, Serena Cutarella1, Roberto Cuomo5, Luca Grimaldi5, Pietro Rubegni3, Michele Maio1|2, Anna Maria Di Giacomo1|2 | 1University of Siena; 2Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena; 3Dermatology Unit, Department of Medicine, Surgery and Neuroscience, University Hospital of Siena; 4Radiotherapy Unit, Department of Oncology, University Hospital of Siena; 5Plastic Surgery Unit, Department of Medicine, Surgery and Neuroscience, University Hospital of Siena; 6NIBIT Foundation Onlus, Genoa, Italy.
314 -
34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo1|2, Bruna Dalmasso3, Maria Chiara Scaini4, Laura Cendron5, Monica Rodolfo6, Ilaria Mattavelli7, Elena Tamborini8, Francesca Collina9, Gerardo Ferrara, Gabriele Madonna10, Carlo Cota11, Elisa Melucci12, Stefania Tommasi13, Martina Ubaldi14, Roberta Depenni15, Andrea Carugno16, Riccardo Marconcini17, Laura Orgiano18, Maurizio Lombardo19, Simona Sola20, Cristina Pellegrini21, Francesca Castiglione22, Matteo Gasparotto5|23, Alireza Jorkesh5, Stefania Pellegrini4, Edoardo Raposio1, Andrea Boutros2, Enrica Teresa Tanda2, Michele Guida25, Pietro Quaglino26, Giuseppe Palmieri27, Daniela Massi22, Paolo Antonio Ascierto10, Mario Mandalà*28, Chiara Menin*4, Paola Ghiorzo*24, Lorenza Pastorino*24, for the Italian Melanoma Intergroup29 | 1Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; 2IRCCS Ospedale Policlinico San Martino, Genova; 3IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; 4Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; 5Department of Biology, University of Padua, Padua; 6Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 7Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 8Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 9Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; 10Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; 11Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; 12Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; 13Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; 14Unit of Medical Oncology, University of Perugia; 15Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; 16Department of Medicine and Surgery, University of Insubria, Varese; 17Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; 18Department of Medical Oncology, University of Cagliari, Cagliari; 19Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; 20Surgical Pathology, Galliera Hospital, Genoa; 21Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; 22Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; 23Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 24Department of Internal Medicine and Medical Specialties, University of Genoa; 25Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; 26Dermatology Clinic, Department of Medical Sciences, University of Turin; 27Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; 28University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; 29Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.
320 -
35 | Real-world outcomes of targeted therapy in stage IV melanoma after relapse on adjuvant dabrafenib and trametinib: insights from a single-center cohort Rossella Villani, Chiara Bungaro, Anna Cecere, Ileana De Roma, Sabino Strippoli, Michele Guida | Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
345 -
36 | Neoadjuvant strategy for locally advanced conjunctival melanoma: a single-center approach to eye preservation F. Rifaldi1|2, M. Angi3, L. Giuseppe1, F. Lanza3, A. Spagnoletti1, J. Sergenti3, A. Indini1, E. Mastrogiuseppe3, M. Del Vecchio1, L. Di Guardo1 | 1Melanoma Medical Oncology Unit, Department of Medical Oncology ed Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 2Fondazione IRCCS Policlinico San Matteo, Pavia; 3Ocular Oncology Service, Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
377
